Cargando…

Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model

Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors. Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Dwaipayan, Zha, Jiuhong, Menon, Rajeev M., Shebley, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953987/
https://www.ncbi.nlm.nih.gov/pubmed/29427135
http://dx.doi.org/10.1007/s10928-018-9574-0
_version_ 1783323428508401664
author Mukherjee, Dwaipayan
Zha, Jiuhong
Menon, Rajeev M.
Shebley, Mohamad
author_facet Mukherjee, Dwaipayan
Zha, Jiuhong
Menon, Rajeev M.
Shebley, Mohamad
author_sort Mukherjee, Dwaipayan
collection PubMed
description Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors. Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatment regimens. Drug–drug interaction (DDI) between RTV and amlodipine is due to mixed inhibition and induction of CYP3A4, which is challenging to predict without a mechanistic model that accounts for the complexity of both mechanisms occurring simultaneously. A novel physiologically-based pharmacokinetic (PBPK) model was developed for amlodipine, and the model was verified using published clinical PK and DDI data. The verified amlodipine PBPK model was linked to a pharmacodynamics model that describes changes in systolic blood pressure (SBP) during and after co-administration with RTV. The magnitude and time course of RTV effects on amlodipine plasma exposures and SBP were evaluated, to provide guidance on dose adjustment of amlodipine during and after co-administration with RTV-containing regimens. Model simulations suggested that the increase in amlodipine’s plasma exposure by RTV diminishes by approximately 80% within 5 days after the last dose of RTV. PBPK simulations suggested that resuming a full dose of amlodipine [5 mg once daily (QD)] immediately after RTV’s last dose would decrease daily average SBP by a maximum of 3.3 mmHg, while continuing with the reduced dose (2.5 mg QD) for 5 days after the last dose of RTV would increase daily average SBP by a maximum of 5.8 mmHg. Based on these results, either approach of resuming amlodipine’s full dose could be appropriate when combined with appropriate clinical monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10928-018-9574-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5953987
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-59539872018-05-18 Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model Mukherjee, Dwaipayan Zha, Jiuhong Menon, Rajeev M. Shebley, Mohamad J Pharmacokinet Pharmacodyn Original Paper Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors. Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatment regimens. Drug–drug interaction (DDI) between RTV and amlodipine is due to mixed inhibition and induction of CYP3A4, which is challenging to predict without a mechanistic model that accounts for the complexity of both mechanisms occurring simultaneously. A novel physiologically-based pharmacokinetic (PBPK) model was developed for amlodipine, and the model was verified using published clinical PK and DDI data. The verified amlodipine PBPK model was linked to a pharmacodynamics model that describes changes in systolic blood pressure (SBP) during and after co-administration with RTV. The magnitude and time course of RTV effects on amlodipine plasma exposures and SBP were evaluated, to provide guidance on dose adjustment of amlodipine during and after co-administration with RTV-containing regimens. Model simulations suggested that the increase in amlodipine’s plasma exposure by RTV diminishes by approximately 80% within 5 days after the last dose of RTV. PBPK simulations suggested that resuming a full dose of amlodipine [5 mg once daily (QD)] immediately after RTV’s last dose would decrease daily average SBP by a maximum of 3.3 mmHg, while continuing with the reduced dose (2.5 mg QD) for 5 days after the last dose of RTV would increase daily average SBP by a maximum of 5.8 mmHg. Based on these results, either approach of resuming amlodipine’s full dose could be appropriate when combined with appropriate clinical monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10928-018-9574-0) contains supplementary material, which is available to authorized users. Springer US 2018-02-09 2018 /pmc/articles/PMC5953987/ /pubmed/29427135 http://dx.doi.org/10.1007/s10928-018-9574-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Mukherjee, Dwaipayan
Zha, Jiuhong
Menon, Rajeev M.
Shebley, Mohamad
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
title Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
title_full Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
title_fullStr Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
title_full_unstemmed Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
title_short Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
title_sort guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953987/
https://www.ncbi.nlm.nih.gov/pubmed/29427135
http://dx.doi.org/10.1007/s10928-018-9574-0
work_keys_str_mv AT mukherjeedwaipayan guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel
AT zhajiuhong guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel
AT menonrajeevm guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel
AT shebleymohamad guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel